|
1
|
Yin H, Sun L, Pu Y, Yu J, Feng W, Dong C,
Zhou B, Du D, Zhang Y, Chen Y and Xu H: Ultrasound-Controlled
CRISPR/Cas9 system augments sonodynamic therapy of hepatocellular
carcinoma. ACS Cent Sci. 7:2049–2062. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lai JP, Sandhu DS, Yu C, Han T, Moser CD,
Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, et
al: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth
factor signaling, and decreases survival in hepatocellular
carcinoma. Hepatology. 47:1211–1222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cabibbo G, Enea M, Attanasio M, Bruix J,
Craxi A and Camma C: A meta-analysis of survival rates of untreated
patients in randomized clinical trials of hepatocellular carcinoma.
Hepatology. 51:1274–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu
J, Liu S, Yu M, Chen J, Wang S, et al: An RNA-RNA crosstalk network
involving HMGB1 and RICTOR facilitates hepatocellular carcinoma
tumorigenesis by promoting glutamine metabolism and impedes
immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target
Ther. 6:4212021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao W, Kim H, Feng M, Phung Y, Xavier CP,
Rubin JS and Ho M: Inactivation of Wnt signaling by a human
antibody that recognizes the heparan sulfate chains of glypican-3
for liver cancer therapy. Hepatology. 60:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Knelson EH, Gaviglio AL, Nee JC, Starr MD,
Nixon AB, Marcus SG and Blobe GC: Stromal heparan sulfate
differentiates neuroblasts to suppress neuroblastoma growth. J Clin
Invest. 124:3016–3031. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cui X, Li Z, Gao PJ, Gao J and Zhu JY:
Prognostic value of glypican-3 in patients with HBV-associated
hepatocellular carcinoma after liver transplantation. Hepatobiliary
Pancreat Dis Int. 14:157–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu SJ, Qi CY, Xiao WK, Li SQ, Peng BG and
Liang LJ: Glypican-3 is a potential prognostic biomarker for
hepatocellular carcinoma after curative resection. Surgery.
154:536–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Q, Han Z, Tao J, Zhao M, Zhang W, Li
P, Tang L and Gu Y: An innovative peptide with high affinity to
GPC3 for hepatocellular carcinoma diagnosis. Biomater Sci.
7:159–167. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia L, Teng Q, Chen Q and Zhang F:
Preparation and characterization of anti-GPC3 nanobody against
hepatocellular carcinoma. Int J Nanomedicine. 15:2197–2205. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Du K, Li Y, Liu J, Chen W, Wei Z, Luo Y,
Liu H, Qi Y, Wang F and Sui J: A bispecific antibody targeting GPC3
and CD47 induced enhanced antitumor efficacy against dual
antigen-expressing HCC. Mol Ther. 29:1572–1584. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu M, Luo H, Fan M, Wu X, Shi B, Di S, Liu
Y, Pan Z, Jiang H and Li Z: Development of GPC3-specific chimeric
antigen receptor-engineered natural killer cells for the treatment
of hepatocellular carcinoma. Mol Ther. 26:366–378. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi
J, Lu Q, Gao H, Jiang H, Wang H, et al: Chimeric antigen
receptor-glypican-3 T-cell therapy for advanced hepatocellular
carcinoma: Results of phase I trials. Clin Cancer Res.
26:3979–3989. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang CH, Kim Y, Lee DY, Choi SU and Lee
HK: Park CH. c-Met-Specific chimeric antigen receptor T cells
demonstrate anti-tumor effect in c-met positive gastric cancer.
Cancers (Basel). 13:57382021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mansilla-Soto J, Eyquem J, Haubner S,
Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjostrand M,
Lindenbergh PL, et al: HLA-independent T cell receptors for
targeting tumors with low antigen density. Nat Med. 28:345–352.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang SS, Luong K, Gracey FM, Jabar S,
McColl B, Cross RS and Jenkins MR: A novel peptide-MHC targeted
chimeric antigen receptor T cell forms a T cell-like immune
synapse. Biomedicines. 9:18752021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsimberidou AM, Van Morris K, Vo HH, Eck
S, Lin YF, Rivas JM and Andersson BS: T-cell receptor-based
therapy: An innovative therapeutic approach for solid tumors. J
Hematol Oncol. 14:1022021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Consonni M, Garavaglia C, Grilli A, de
Lalla C, Mancino A, Mori L, De Libero G, Montagna D, Casucci M,
Serafini M, et al: Human T cells engineered with a leukemia
lipid-specific TCR enables donor-unrestricted recognition of
CD1c-expressing leukemia. Nat Commun. 12:48442021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao
Q, Dao L, Xia X, Natalie Wall F, Zhang Z, et al: Cell
membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy
for eliminating large and heterogeneous solid tumors. J Immunother
Cancer. 10:e0036332022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meyran D, Terry RL, Zhu JJ, Haber M,
Ziegler DS, Ekert PG, Trapani JA, Darcy PK and Neeson PJ:
Early-phenotype CAR-T cells for the treatment of pediatric cancers.
Ann Oncol. 32:1366–1380. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lemoine J, Ruella M and Houot R: Born to
survive: How cancer cells resist CAR T cell therapy. J Hematol
Oncol. 14:1992021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greenbaum U, Dumbrava EI, Biter AB,
Haymaker CL and Hong DS: Engineered T-cell receptor T cells for
cancer immunotherapy. Cancer Immunol Res. 9:1252–1261. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Sharma P and Allison JP: Immune checkpoint
targeting in cancer therapy: Toward combination strategies with
curative potential. Cell. 161:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y
and Xia Y: Improvement of the anticancer efficacy of PD-1/PD-L1
blockade via combination therapy and PD-L1 regulation. J Hematol
Oncol. 15:242022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen N, Yang C, Zhang X, Tang Z and Chen
X: Cisplatin nanoparticles possess stronger anti-tumor synergy with
PD1/PD-L1 inhibitors than the parental drug. Acta Biomater.
135:543–555. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang W, Li T, Guo J, Wang J, Jia L, Shi
X, Yang T, Jiao R, Wei X, Feng Z, et al: Bispecific c-Met/PD-L1
CAR-T cells have enhanced therapeutic effects on hepatocellular
carcinoma. Front Oncol. 11:5465862021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan X, Sun Z, Yuan Q, Hou W, Liang Q,
Wang Y, Mo W, Wang H and Yu M: Dual-function chimeric antigen
receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor
efficacy in solid tumors. Invest New Drugs. 39:34–51. 2021.
View Article : Google Scholar
|
|
30
|
Zheng X, Liu X, Lei Y, Wang G and Liu M:
Glypican-3: A novel and promising target for the treatment of
hepatocellular carcinoma. Front Oncol. 12:8242082022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia
M, Li N, Lu P, Sun B, et al: Shed antigen-induced blocking effect
on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma. J
Immunother Cancer. 9:e0018752021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jacoby E, Shahani SA and Shah NN: Updates
on CAR T-cell therapy in B-cell malignancies. Immunol Rev.
290:39–59. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gauthier J, Bezerra ED, Hirayama AV,
Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM,
Vakil A, et al: Factors associated with outcomes after a second
CD19-targeted CAR T-cell infusion for refractory B-cell
malignancies. Blood. 137:323–335. 2021. View Article : Google Scholar :
|
|
34
|
Frigault MJ, Dietrich J, Martinez-Lage M,
Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J,
Armand P, et al: Tisagenlecleucel CAR T-cell therapy in secondary
CNS lymphoma. Blood. 134:860–866. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang ZZ, Wang T, Wang XF, Zhang YQ, Song
SX and Ma CQ: Improving the ability of CAR-T cells to hit solid
tumors: Challenges and strategies. Pharmacol Res. 175:1060362022.
View Article : Google Scholar
|
|
36
|
Shen L, Xiao Y, Tian J and Lu Z:
Remodeling metabolic fitness: Strategies for improving the efficacy
of chimeric antigen receptor T cell therapy. Cancer Lett.
529:139–152. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dana H, Chalbatani GM, Jalali SA, Mirzaei
HR, Grupp SA, Suarez ER, Raposo C and Webster TJ: CAR-T cells:
Early successes in blood cancer and challenges in solid tumors.
Acta Pharm Sin B. 11:1129–1147. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Akbari P, Huijbers EJM, Themeli M,
Griffioen AW and van Beijnum JR: The tumor vasculature an
attractive CAR T cell target in solid tumors. Angiogenesis.
22:473–475. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dammeijer F, van Gulijk M, Mulder EE,
Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP,
Latupeirissa K, Schetters S, et al: The PD-1/PD-L1-checkpoint
restrains T cell immunity in tumor-draining lymph nodes. Cancer
Cell. 38:685–700.e8. 2020. View Article : Google Scholar
|
|
40
|
Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu
Y, Yang Q, Nie J, Tang N, Zhang X, et al: Phase I study of CAR-T
cells with PD-1 and TCR disruption in mesothelin-positive solid
tumors. Cell Mol Immunol. 18:2188–2198. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kato D, Yaguchi T, Iwata T, Katoh Y, Morii
K, Tsubota K, Takise Y, Tamiya M, Kamada H, Akiba H, et al: GPC1
specific CAR-T cells eradicate established solid tumor without
adverse effects and synergize with anti-PD-1 Ab. Elife.
9:e493922020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi X, Zhang D, Li F, Zhang Z, Wang S,
Xuan Y, Ping Y and Zhang Y: Targeting glycosylation of PD-1 to
enhance CAR-T cell cytotoxicity. J Hematol Oncol. 12:1272019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Restifo NP, Dudley ME and Rosenberg SA:
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nat Rev Immunol. 12:269–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
O'Connell J, O'Sullivan GC, Collins JK and
Shanahan F: The Fas counterattack: Fas-mediated T cell killing by
colon cancer cells expressing Fas ligand. J Exp Med. 184:1075–1082.
1996. View Article : Google Scholar : PubMed/NCBI
|
